Welcome to our dedicated page for Pelthos Therapeutics SEC filings (Ticker: PTHS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Pelthos Therapeutics's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Pelthos Therapeutics's regulatory disclosures and financial reporting.
PTHS Form 4 highlights: On 07/02/2025 Pelthos Therapeutics granted Chief Commercial Officer Sai Rangarao two equity awards.
- Restricted Stock Units: 30,518 RSUs at an exercise price of $13.50. One-third vests 07/02/2026; the balance vests quarterly over the following two years.
- Stock Options: 93,000 options, also at $13.50, with the same vesting schedule and a 07/02/2035 expiration.
No shares were sold; post-grant beneficial ownership equals the 30,518 RSUs and 93,000 options disclosed. The awards represent potential issuance of 123,518 common shares, introducing modest dilution but aligning the C-suite鈥檚 incentives with shareholder value creation. Investors may wish to track cumulative equity grants and future Form 4 filings to gauge insider sentiment and dilution trajectory.
FAQ
What is the current stock price of Pelthos Therapeutics (PTHS)?
What is the market cap of Pelthos Therapeutics (PTHS)?
